Dr. Stephen M. Hahn @SteveFDA · 28m The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients. Quote Tweet U.S. FDA @US_FDA · 29m FDA is alerting clinical lab staff & health care providers that it is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests. https://fda.gov/news-events/press-announcements/fda-issues-alert-regarding-sars-cov-2-viral-mutation-health-care-providers-and-clinical-laboratory… Show this thread 2 7
Dr. Stephen M. Hahn @SteveFDA · 28m We are working with authorized test developers and reviewing incoming data to ensure that health care providers and clinical staff can quickly and accurately diagnose patients infected with SARS-CoV-2, including those with emerging genetic variants. 1 9
Christian @b2e9f523 · 6m Replying to @SteveFDA So MedMira's enhanced REVEALCOVID-19 PLUS Total Antibody Test for the simultaneous detection of antibodies to both Nucleocapsid and the the new mutations' Spike proteins will help significantly, right? @medmira @webbdiagnostic